208 related articles for article (PubMed ID: 11687899)
1. BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
Randrianarison V; Marot D; Foray N; Cabannes J; Méret V; Connault E; Vitrat N; Opolon P; Perricaudet M; Feunteun J
Cancer Gene Ther; 2001 Oct; 8(10):759-70. PubMed ID: 11687899
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 physically associates with p53 and stimulates its transcriptional activity.
Zhang H; Somasundaram K; Peng Y; Tian H; Zhang H; Bi D; Weber BL; El-Deiry WS
Oncogene; 1998 Apr; 16(13):1713-21. PubMed ID: 9582019
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
Ramondetta L; Mills GB; Burke TW; Wolf JK
Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
[TBL] [Abstract][Full Text] [Related]
4. Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms.
Lu M; Arrick BA
Oncogene; 2000 Dec; 19(54):6351-60. PubMed ID: 11175350
[TBL] [Abstract][Full Text] [Related]
5. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
6. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter.
Chai YL; Cui J; Shao N; Shyam E; Reddy P; Rao VN
Oncogene; 1999 Jan; 18(1):263-8. PubMed ID: 9926942
[TBL] [Abstract][Full Text] [Related]
7. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Somasundaram K; Zhang H; Zeng YX; Houvras Y; Peng Y; Zhang H; Wu GS; Licht JD; Weber BL; El-Deiry WS
Nature; 1997 Sep; 389(6647):187-90. PubMed ID: 9296497
[TBL] [Abstract][Full Text] [Related]
8. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.
Hakem R; de la Pompa JL; Elia A; Potter J; Mak TW
Nat Genet; 1997 Jul; 16(3):298-302. PubMed ID: 9207798
[TBL] [Abstract][Full Text] [Related]
9. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
10. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor activity induced by adenovirus-mediated BRCA1 overexpression is not restricted to breast cancers.
Marot D; Opolon P; Brailly-Tabard S; Elie N; Randrianarison V; Connault E; Foray N; Feunteun J; Perricaudet M
Gene Ther; 2006 Feb; 13(3):235-44. PubMed ID: 16208422
[TBL] [Abstract][Full Text] [Related]
12. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway.
Bao JJ; Le XF; Wang RY; Yuan J; Wang L; Atkinson EN; LaPushin R; Andreeff M; Fang B; Yu Y; Bast RC
Cancer Res; 2002 Dec; 62(24):7264-72. PubMed ID: 12499268
[TBL] [Abstract][Full Text] [Related]
13. Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression.
Kralj M; Husnjak K; Körbler T; Pavelić J
Cancer Gene Ther; 2003 Jun; 10(6):457-67. PubMed ID: 12768191
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ.
Wang TJ; Huang MS; Hong CY; Tse V; Silverberg GD; Hsiao M
Biochem Biophys Res Commun; 2001 Sep; 287(1):173-80. PubMed ID: 11549271
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 signals ARF-dependent stabilization and coactivation of p53.
Somasundaram K; MacLachlan TK; Burns TF; Sgagias M; Cowan KH; Weber BL; el-Deiry WS
Oncogene; 1999 Nov; 18(47):6605-14. PubMed ID: 10597265
[TBL] [Abstract][Full Text] [Related]
16. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.
Wen SF; Mahavni V; Quijano E; Shinoda J; Grace M; Musco-Hobkinson ML; Yang TY; Chen Y; Runnenbaum I; Horowitz J; Maneval D; Hutchins B; Buller R
Cancer Gene Ther; 2003 Mar; 10(3):224-38. PubMed ID: 12637944
[TBL] [Abstract][Full Text] [Related]
17. C-terminal deletion mutant p21(WAF1/CIP1) enhances E2F-1-mediated apoptosis in colon adenocarcinoma cells.
Elliott MJ; Stilwell A; Dong YB; Yang HL; Wong SL; Wrightson WR; Martin RC; McMasters KM
Cancer Gene Ther; 2002 May; 9(5):453-63. PubMed ID: 11961668
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
Modesitt SC; Ramirez P; Zu Z; Bodurka-Bevers D; Gershenson D; Wolf JK
Clin Cancer Res; 2001 Jun; 7(6):1765-72. PubMed ID: 11410518
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse.
Kim J; Hwang ES; Kim JS; You EH; Lee SH; Lee JH
Cancer Gene Ther; 1999; 6(2):172-8. PubMed ID: 10195884
[TBL] [Abstract][Full Text] [Related]
20. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene.
Abramovitch S; Werner H
Horm Metab Res; 2003; 35(11-12):758-62. PubMed ID: 14710355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]